Neisseria gonorrhoeae Antimicrobial Resistance: The Future of Antibiotic Therapy
Journal of Clinical Medicine · 18.12.2023 · 12 (24) · 7767
DOI: 10.3390/jcm12247767 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.12.2023. Verfasst von Angelo Roberto Raccagni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The growing threat of antibiotic-resistant Neisseria gonorrhoeae, which causes gonorrhea, presents a current public health challenge. Over the years, the pathogen has developed resistance to different antibiotics, leaving few effective treatment options. High-level resistance to key drugs, including ceftriaxone, has become a concerning reality. This article primarily focuses on the treatment of gonorrhea and the current clinical trials aimed at providing new antibiotic treatment options. We explore ongoing efforts to assess new antibiotics, including zoliflodacin, and gepotidacin. These drugs offer new effective treatment options, but their rapid availability remains uncertain. We delve into two ongoing clinical trials: one evaluating the efficacy and safety of gepotidacin compared to the standard ceftriaxone–azithromycin combination and the other assessing the non-inferiority of zoliflodacin versus the combination therapy of ceftriaxone–azithromycin. These trials represent crucial steps in the search for alternative treatments for uncomplicated gonorrhea. Notably, gonorrhea has been included in the “WHO Priority Pathogens List for Research and Development of New Antibiotics”. In conclusion, the urgent need for innovative treatment strategies is underscored by the rising threat of antibiotic resistance in N. gonorrhoeae; collaboration among researchers, industries, and healthcare authorities is therefore essential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy.
- Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
ORCID-Profile: Angelo Roberto Raccagni, Silvia Nozza
Zitieren
APA
Raccagni, A. R., Ranzenigo, M., Bruzzesi, E., Maci, C., Castagna, A., & Nozza, S. (2023). Neisseria gonorrhoeae Antimicrobial Resistance: The Future of Antibiotic Therapy. Journal of Clinical Medicine, 12(24), 7767. https://doi.org/10.3390/jcm12247767
Vancouver
Raccagni AR, Ranzenigo M, Bruzzesi E, Maci C, Castagna A, Nozza S. Neisseria gonorrhoeae Antimicrobial Resistance: The Future of Antibiotic Therapy. Journal of Clinical Medicine. 2023;12(24):7767. doi:10.3390/jcm12247767
BibTeX
@article{Raccagni2023,
author = {Raccagni, Angelo Roberto and Ranzenigo, Martina and Bruzzesi, Elena and Maci, Chiara and Castagna, Antonella and Nozza, Silvia},
title = {Neisseria gonorrhoeae Antimicrobial Resistance: The Future of Antibiotic Therapy},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {24},
pages = {7767},
doi = {10.3390/jcm12247767}
}
EUVIMED